Innovation Centre
Manufacturing · United Kingdom · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Milton Park Innovation Centre 99 Park Dr...Phone Number
+44 1235644970Website
www.greywolftherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Innovation Centre
Greywolf Therapeutics specializes in novel antigen modulation technology that controls T cells to guide the immune system, addressing challenges in oncology, autoimmune disorders, and infectious diseases. Their innovative approach modifies antigen presentation within cells, enhancing T cell recognition and targeting. The company is actively developing treatments to tackle immune dysfunction and has demonstrated promising results in clinical trials, particularly with their lead modulator GRWD5769. Greywolf Therapeutics is committed to exploring the untapped potential of T cell signaling to shift treatment paradigms for patients facing significant health challenges.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Innovation Centre your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Innovation Centre has new funding data
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Innovation Centre recently announced quarterly report
Check if Innovation Centre has recently received funding, and reach out quickly before it becomes old news!
Click to see if Innovation Centre had a recent Job posting/layoffs
Innovation Centre, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Innovation Centre launches new products
Check out if Innovation Centre is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Innovation Centre
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Innovation Centre
Compare insights from companies similar to Innovation Centre, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Innovation Centre
<$5M
11-50
Private
$106M
2017
N/A
Company Profile Activity
Activity Insights
Innovation Centre is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Innovation Centre is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Innovation Centre.
Innovation Centre financials insights
Gather financial insights about Innovation Centre, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Series A
$7M
2024
Series B
$99M
Innovation Centre Tech Stack
A closer look at the technologies used by Innovation Centre
Most Recent Scoops
Open Position
New Hire
Executive Move
Executive Moves, New Hire
Funding
Funding
Funding
Innovation Centre News & Media
Greywolf Therapeutics begins dosing of the first treatment to target the antigenic source of autoimmunity
Greywolf starts first trial of GRWD0715, aiming for a functional cure for autoimmunity by targeting its antigenic source.Greywolf Appoints Darlene Deptula-Hicks as Chief Financial Officer
OXFORD, England--(BUSINESS WIRE)--Greywolf Therapeutics, a clinical-stage biotech company advancing novel antigen modulation technology that controls T cells to guide the immune system, has appointed Darlene Deptula-Hicks as Chief Financial Officer. An accomplished biotech and healthcare executive, Ms. Deptula-Hicks most recently served as Chief Financial Officer of F-star Therapeutics Inc. (FSTX), which she took public on the NASDAQ in 2020, through to the successful sale of the company in 202Grey Wolf Therapeutics Closes Oversubscribed $50 Million Series B Financing Expansion, Led by ICG Life Sciences Team, to Accelerate and Expand First-of-its-Kind Antigen Modulation Technology
Brings Total Series B Funds Raised to Nearly $100 Million Proceeds to Support Broadening Scope of Ongoing Clinical Trial of GRWD5769; First Clinical Data to be Reported at ASCO 2024 Company to Expand R&D Efforts to Develop Disease-Modifying Therapies for Autoimmune Disorders OXFORD, UK,...Grey Wolf Raises $49m To Bring 'Tumor Unmasking' Candidate To Clinic - Scrip
The UK biotech will use the funds to advance the development of its first-in-class ERAP1 inhibitor, which could circumvent the limitations of poor tumor visibility and T cell exhaustion.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Innovation Centre
Sign Up For FreeTo access detailed company insights
Greywolf Therapeutics specializes in novel antigen modulation technology that controls T cells to guide the immune system, addressing challenges in oncology, autoimmune disorders, and infectious diseases. Their innovative approach modifies antigen presentation within cells, enhancing T cell recognition and targeting. The company is actively develop... Read More
